Vertical integration continues to reshape U.S. healthcare, as detailed in DCI’s new 2025-26 Economic Report on Pharmaceutical Wholesalers and Specialty Distributors. Our latest analysis shows how the Big Three companies—Cencora, Cardinal Health, and McKesson—are extending their reach far beyond drug distribution, building influence throughout the drug channel. In recent years, these companies have spent more than $16 billion to acquire management service organizations (MSOs) that overse...| Drug Channels
I am pleased to announce Drug Channels Institute’s new 2025-26 Economic Report on Pharmaceutical Wholesalers and Specialty Distributors, available for purchase and immediate download. Download a free 25-page report overview—including key industry trends, “What's New,” Table of Contents, and List of Exhibits Review pricing/license options and download the full 2025-26 report Special launch pricing is available through October 27, 2025. This report—our sixteenth edition—remains the ...| Drug Channels
Posted in Announcement, News| RX-Info
This week, I’m rerunning some popular posts while I put the finishing touches on DCI’s 2025-26 Economic Report on Pharmaceutical Wholesalers and Specialty Distributors. Click here to see the original post from July 2025. ICYMI, Express Scripts will boot the reference products from its 2026 formulary, but will cling to its biosimilar pricing double standard. --- The 2025 launch of biosimilars to Johnson & Johnson’s Stelara (ustekinumab) marks another turning point in pharmacy benefit dyn...| Drug Channels
On October 14, 2025, Drug Channels Institute will release our 2025-26 Economic Report on Pharmaceutical Wholesalers and Specialty Distributors. This report—our sixteenth edition—is the most comprehensive, fact-based tool for understanding and analyzing the large and growing U.S. pharmaceutical distribution industry. With 9 chapters, 400+ pages, 187 exhibits, and 850+ endnotes, this report is unmatched in scope and depth. There is no other resource like it. Preorder today to secure this fu...| Drug Channels
In April 2023, I received a letter from the Ontario government with information about the new biosimilar switching policy. I had until the end of the year to switch from the biologic medication I take to treat my rheumatoid arthritis (RA) to a biosimilar. I did my best to be hopeful and believe it would…| The Seated View